The Park Square team is thrilled to support Deep Genomics and their unique, AI-driven approach to discovering and developing genetic medicines.
Deep Genomics, the leading AI therapeutics company, announced today that the output of its discovery pipeline has quadrupled in the past year and that it has appointed Johan Fransson, Ph.D. as Head of Preclinical Research, effective immediately. “We have discovered dozens of novel targets that can address the unmet need of tens of thousands of patients suffering from rare genetic disorders,” said Brendan Frey, Founder and Chief Executive Officer. “At this time, we require a leader with experience in building and managing teams that can take programs from target validation to candidate declaration and IND application,” said Frey. “I am pleased to announce that Johan Fransson has joined us to take on this responsibility. Johan’s experience with preclinical research in big pharma and biotech startups, and his openness to an AI-accelerated approach to discovery, makes him ideal for this role.”